Article
The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.
PloS one - 1 Jan 2015
Berghauser Pont Lotte M E, Kleijn Anne, Kloezeman Jenneke J, van den Bossche Wouter, Kaufmann Johanna K, de Vrij Jeroen, Leenstra Sieger, Dirven Clemens M F, Lamfers Martine L M
Abstract excerpt
BACKGROUND: A phase I/II trial for glioblastoma with the oncolytic adenovirus Delta24-RGD was recently completed. Delta24-RGD conditionally replicates in cells with a disrupted retinoblastoma-pathway and enters cells via αvβ3/5 integrins. Glioblastomas are differentially sensitive to Delta24-RGD. HDAC inhibitors (HDACi) affect integrins and share common cell death pathways with Delta24-RGD. We studied the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.